| Name | Blonanserin |
| Description | Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension. |
| In vitro | In tests of atypical antipsychotics (risperidone, olanzapine, and aripiprazole), Blonanserin showed the most potent binding affinity for human D3 receptors.Blonanserin transiently increased neuronal firing in the nucleus of the pallidum and ventral tegmental area, but not in the nucleus medius dorsalis or the medial dorsal nucleus of the thalamus, whereas risperidone increased firing in the nucleus ventral tegmental area and in the nucleus medius dorsalis but not in the nucleus dorsalis. in the medial dorsal nucleus of the rat thalamus. Blonanserin consistently increased additional extracellular levels of norepinephrine and dopamine but not serotonin, GABA, or glutamate, whereas risperidone consistently increased levels of norepinephrine, dopamine, and serotonin but not GABA or glutamate.Blonanserin increased the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxy Phenylacetic acid. |
| In vivo | In tests of atypical antipsychotics (risperidone, olanzapine, and aripiprazole), Blonanserin showed the most potent binding affinity for human D3 receptors.Blonanserin transiently increased neuronal firing in the nucleus of the pallidum and ventral tegmental area, but not in the nucleus medius dorsalis or the medial dorsal nucleus of the thalamus, whereas risperidone increased firing in the nucleus ventral tegmental area and in the nucleus medius dorsalis but not in the nucleus dorsalis. in the medial dorsal nucleus of the rat thalamus. Blonanserin consistently increased additional extracellular levels of norepinephrine and dopamine but not serotonin, GABA, or glutamate, whereas risperidone consistently increased levels of norepinephrine, dopamine, and serotonin but not GABA or glutamate.Blonanserin increased the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxy Phenylacetic acid. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1.00 mg/mL (2.72 mM), Sonication is recommended.
DMSO : 14.29 mg/mL (38.88 mM), Sonication is recommended.
|
| Keywords | social deficit | Sigmareceptor | Sigma Receptor | Serotonin Receptor | schizophrenia | Inhibitor | inhibit | hypotension | extrapyramidal symptom | excessive sedation | DopamineReceptor | Dopamine Receptor | Dopamine | D2 | Blonanserin | Beta Receptor | antipsychotic | AdrenergicReceptor | Adrenergic Receptor | AD5423 | AD 5423 | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT2 | 5-HT Receptor | 5HT Receptor |
| Inhibitors Related | Alverine citrate | Dapoxetine hydrochloride | Cefaclor monohydrate | Hexamethonium Bromide | Octopamine hydrochloride | 1,8-Cineole | L-DOPA | Isoprenaline hydrochloride | Creatine | D-Mannitol | Mianserin hydrochloride | Cinchonidine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
